Latest / The Dales Report | Trade to Black
Cybin Receives Expedited Review FDA Breakthrough
In this episode of the Trade to Black Podcast, we sit down with Doug Drysdale, Chief Executive Officer of Cybin, to discuss the recent milestones and future prospects of their novel psychedelic molecule, CYB003. #Cybin #Cybinstock #thedalesreport Key topics covered in this interview: - FDA’s Breakthrough Therapy Designation - Phase 2 Trial Success - The Road to Phase 3 - ICYB003’s fast onset of effects and its implications - Financial Strategy Insight Get a glimpse into the key milestones and developments expected in Cybin’s pipeline, focusing on Psilocybin, DMT/d-DMT, and Phenethylamines…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.